Physician profile
Sammy Moghazi
NPI 1215915269
$55,603.62
in general payments reported to CMS, 2019-2025
31 companies · $1,076 in 2025
The $1,076 reported for 2025 was more than what 79% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,739 · 2020: $6,745 · 2021: $6,125 · 2022: $8,995 · 2023: $12K · 2024: $18K · 2025: $1,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $16K · Honoraria: $8,800 · Food and Beverage: $4,000 · Travel and Lodging: $2,012 · Consulting Fee: $762 · Education: $114.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,312.50 |
| Honoraria | $8,800.00 |
| Food and Beverage | $3,999.99 |
| Travel and Lodging | $2,011.71 |
| Consulting Fee | $762.00 |
| Education | $113.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $23,230.87 | 2019-2023 | Krystexxa |
| Amgen INC. | $19,586.50 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Scpharmaceuticals INC. | $6,387.89 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $2,180.56 | 2019-2025 | Lokelma, Farxiga |
| Fresenius USA Marketing, INC. | $589.54 | 2019-2025 | Velphoro, Velphoro, Korsuva |
| Otsuka America Pharmaceutical, INC. | $477.94 | 2019-2025 | Jynarque |
| Vifor Pharma, INC. | $472.97 | 2019-2025 | Veltassa |
| Mallinckrodt Hospital Products INC. | $345.97 | 2020-2025 | Acthar |
| Travere Therapeutics, INC. | $297.62 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $265.71 | 2019-2024 | Ultomiris, Soliris |
| Bayer Healthcare Pharmaceuticals INC. | $231.98 | 2021-2025 | |
| Ardelyx, INC. | $209.86 | 2024-2025 | Ibsrela |
| Akebia Therapeutics INC | $189.31 | 2019-2021 | |
| Aurinia Pharma U.S., INC. | $154.96 | 2022-2025 | Lupkynis |
| Calliditas Therapeutics US INC. | $125.12 | 2022-2025 | Tarpeyo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $116.10 | 2021-2025 | Benlysta |
| Opko Pharmaceuticals, LLC | $100.35 | 2020-2023 | Rayaldee |
| Novo Nordisk INC | $91.46 | 2024-2025 | Wegovy, Ozempic |
| Genzyme Corporation | $90.37 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.88 | 2024-2025 | Jardiance |
| Mallinckrodt Enterprises LLC | $75.57 | 2019 | |
| Lilly USA, LLC | $69.83 | 2024-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $62.24 | 2023-2024 | |
| Daiichi Sankyo INC. | $32.83 | 2019-2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $28.69 | 2023 | Jynarque |
| Ani Pharmaceuticals, INC. | $21.83 | 2022 | |
| Kyowa Kirin, INC. | $21.34 | 2023 | Crysvita |
| Shire North American Group INC | $17.91 | 2019 | |
| Apellis Pharmaceuticals, INC. | $17.84 | 2025 | Empaveli |
| Nxstage Medical, INC. | $17.67 | 2019 | |
| Nuwellis, INC. | $14.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sammy Moghazi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.